Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | RORA | P35398 | 1/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.57 |
| ▸ | RORB | Q92753 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022059 | 0.96 | RORC (0.59) | RORC | |
| SCHEMBL5022517 | 0.95 | RORC (0.65) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5023728 | 0.95 | RORC (0.59) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5022483 | 0.93 | RORC (0.66) | RORC | |
| SCHEMBL5022062 | 0.92 | RORC (0.67) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5022063 | 0.92 | RORC (0.66) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5022582 | 0.92 | RORC (0.59) | RORC | |
| SCHEMBL4559536 | 0.91 | RORC (0.56) | RORC | |
| SCHEMBL5022010 | 0.91 | RORC (0.65) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL15611047 | 0.91 | RORC (0.65) | RORCNR1I2RORANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638014-B1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR-GAMMA ACTIVITY AND THE TREATMENT OF DISEASES | LYCERA CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9512111-B2 | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512111-B2 | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2012064744-A2 | TETRAHYDROQUINOLINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORϒ ACTIVITY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | RORC 1/4885NR1I2 9/4885RORA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.